Rick Doblin
This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Rick Doblin | |
|---|---|
 | |
| Name | Rick Doblin |
| Birth date | 1953 |
| Birth place | Boston, Massachusetts |
| Occupation | Activist, researcher, founder |
| Known for | Psychedelic research, Multidisciplinary Association for Psychedelic Studies |
Rick Doblin is an American activist and researcher known for founding the Multidisciplinary Association for Psychedelic Studies (MAPS) and promoting clinical research into MDMA-, psilocybin-, and LSD-assisted psychotherapy. He has been a prominent figure in efforts to change regulatory policy and public perceptions about psychedelic-assisted therapies in the United States and internationally. Doblin's work connects clinical trials, nonprofit leadership, academic collaborations, and policy advocacy.
Early life and education
Doblin was born in Boston, Massachusetts and raised in the New England region. He studied at the New College of Florida before completing a Ph.D. in public policy at the Harvard Kennedy School where his dissertation focused on regulatory pathways for psychedelic-assisted therapies. Earlier academic influences included work with researchers at the Multidisciplinary Association for Psychedelic Studies (MAPS) (later founded by him), mentors and collaborators from institutions such as the Massachusetts Institute of Technology, Johns Hopkins University, and European research centers. His educational background combined interests in public policy, psychotherapy, and substance regulation.
Career and MAPS founding
Doblin founded the Multidisciplinary Association for Psychedelic Studies in the mid-1980s to support scientific research, education, and legal access related to psychedelics. Through MAPS he has coordinated grantmaking, protocol development, and regulatory submissions with agencies including the U.S. Food and Drug Administration, the Drug Enforcement Administration, and international regulators such as the European Medicines Agency. MAPS under Doblin formed collaborations with academic centers like Johns Hopkins University, Imperial College London, New York University, and clinical sites in Canada and Israel. His nonprofit leadership involved fundraising, board governance, and partnerships with organizations such as the Heffter Research Institute, the Multidisciplinary Association for Psychedelic Studies (MAPS) Europe, and advocacy networks including Erowid, Psychedelic Science Review, and policy groups focused on drug scheduling reform.
Psychedelic research and advocacy
Doblin steered MAPS to support Phase II and Phase III clinical trials of MDMA-assisted psychotherapy for post-traumatic stress disorder (PTSD), coordinating investigators from institutions like Mount Sinai Health System, UCLA, University of California, San Francisco, and international partners in Israel and Canada. MAPS-sponsored research addressed regulatory endpoints relevant to the U.S. Food and Drug Administration and included safety and efficacy measures common to psychiatric trials. Doblin engaged with policy processes involving the United Nations Office on Drugs and Crime, the World Health Organization, and national scheduling authorities to argue for rescheduling and expanded medical access. He has testified before legislative bodies and interacted with lawmakers from the United States Congress, regulatory officials in the Drug Enforcement Administration, and international delegations regarding clinical pathways and compassionate use.
Publications and public outreach
Doblin produced publications and public commentary advocating for controlled clinical research and trained therapist protocols, publishing reports and position papers distributed by MAPS and presented at conferences such as the Psychedelic Science Conference and academic symposia at Johns Hopkins University and Imperial College London. He has appeared in media outlets and documentaries featuring subjects like Michael Pollan, Ayelet Waldman, Stanislav Grof, and researchers from MAPS Public Benefit Corporation projects. Doblin organized educational initiatives, trainings for clinicians drawing on models from psychodynamic therapy practitioners, cognitive behavioral therapy teams, and psychedelic-assisted therapy training programs connected to universities and hospitals.
Controversies and criticism
Doblin and MAPS have faced criticism on multiple fronts, including debates about study design, community governance, commercialization, and safety. Critics from academic centers such as Johns Hopkins University and commentators affiliated with organizations like Erowid and independent scholars have questioned elements of trial methodology and therapist training standards. Advocacy groups and investigative journalists have raised concerns about conflicts involving private funding, intellectual property strategies linked to MAPS Public Benefit Corporation, and the rapid commercialization of psychedelic-assisted therapies by entrepreneurs connected to biotech firms on Wall Street and in the venture capital sector. Regulatory watchdogs and professional associations have scrutinized consent practices, long-term follow-up protocols, and the scaling of protocols beyond controlled research settings.
Personal life and honors
Doblin has maintained a public profile as a nonprofit executive and advocate with recognition from various civic and research organizations. Honors and mentions have come from networks in psychedelic research, harm reduction advocates, and nonprofit arenas, while MAPS initiatives have received philanthropic support from donors and foundations. He has collaborated with clinicians, researchers, and policy experts across the United States, Canada, and Europe, and continues to be active in debates over medical access, research ethics, and public policy reform regarding psychedelic-assisted therapies.
Category:Psychedelic research Category:American nonprofit executives